Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?
Does Manuel Treatment With Craniosacral Therapy Change the Experience of Dry Mouth in People Who Suffers With Dry Mouth After Cancer in Throat Ore Mouth - a Pilot Study
1 other identifier
interventional
11
1 country
2
Brief Summary
The current study aims to assess the efficacy of manual treatment with craniosacral therapy of fascial tissue in throat, neck, cranial and mouth region, on radiation and/or surgery-induced salivary gland hypofunction and xerostomia in patients who have received surgery and/or radiation therapy because of cancer in the throat and mouth regions. The hypothesis of this project is based on a recent clinical case treated by me: I practice as a physiotherapist and craniosacral therapist in a private clinic. The patient in question was treated with craniosarcal techniques (techniques that, in a broad sense, mobilizes the fascia, including meninges, dura, sleeves around the nerve-tissue etc.). He suffered from xerostomia and hyposaliva after neck surgery and radiation therapy four years prior to my treatment. During the second treatment of fascial release of the scar tissue and of the tissue around atlas, axis and occiput the patient strongly felt that his saliva started flowing. He received an additional 3 treatments, with fascial release techniques in neck, throat meninges and mouth regions, and three months after his last treatment the patient still reported much better production of saliva than before start of treatment. Furthermore, the patient reported significant gains in ease of speaking and eating. This project aim to assess if this was only an isolated event or if craniosacral therapy could be an evidence based method to increase saliva production and decrease xerostomia for patients after surgical and radiation therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2022
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 4, 2021
CompletedStudy Start
First participant enrolled
March 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 20, 2023
CompletedFirst Posted
Study publicly available on registry
May 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 27, 2023
CompletedResults Posted
Study results publicly available
May 14, 2025
CompletedMay 14, 2025
April 1, 2025
10 months
October 4, 2021
January 22, 2024
April 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Xerostomia Questionnaire
A Danish questionnaire for following up on patients who have finished their cancer treatment in head and neck on a Danish hospital. It is used at least 3 months after treatment. The participants in this study has finished their treatment for cancer at least two years from enroling this study. VAS xerostomia scale0-10 (10 is worst) The remaining 14 questions were phrased "how much does \[question subject\] bother you:" (translated from Danish) not at all (1) - a little (2) - some (3) a lot (4) very much( 5) The final question(number 15) were: "How would you feel, if you had to live the rest of your life, with the symptoms you have now?:" enjoyable(1), very satisfied (2) neither satisfied ore unsatisfied(3), very unsatisfied(4), terrible(5) the sum of points from the 15 questions gives an overall score.
Baseline (before start of this study intervention, but at least two years after finishing treatment of cancer)
Xerostomia Questionnaire
A Danish questionnaire for following up on patients who have finished their cancer treatment in head and neck on a Danish hospital. It is used at least 3 months after treatment. The participants in this study has finished their treatment for cancer at least two years from enroling this study. VAS xerostomia scale0-10 (10 is worst) The remaining 14 questions were phrased "how much does \[question subject\] bother you:" (translated from Danish) not at all (1) - a little (2) - some (3) a lot (4) very much( 5) The final question(number 15) were: "How would you feel, if you had to live the rest of your life, with the symptoms you have now?:" enjoyable(1), very satisfied (2) neither satisfied ore unsatisfied(3), very unsatisfied(4), terrible(5) The sum of points from the 15 questions gives an overall score.
At the start of the fifth and last treament (intervention of this study). .
Xerostomia Questionnaire
A Danish questionnaire for following up on patients who have finished their cancer treatment in head and neck on a Danish hospital. It is used at least 3 months after treatment. The participants in this study has finished their treatment for cancer at least two years from enroling this study. VAS xerostomia scale0-10 (10 is worst) The remaining 14 questions were phrased "how much does \[question subject\] bother you:" (translated from Danish) not at all (1) - a little (2) - some (3) a lot (4) very much( 5) The final question(number 15) were: "How would you feel, if you had to live the rest of your life, with the symptoms you have now?:" enjoyable(1), very satisfied (2) neither satisfied ore unsatisfied(3), very unsatisfied(4), terrible(5) The sum of points from the 15 questions gives an overall score.
6 months post after finishing the craniosacral treatment (the intervention in this study)
Secondary Outcomes (3)
Late Sequelae at Baseline
baseline
Number of Partcipants Who Experienced a Decrease in Symptoms With Their Late Sequela the 5. Time of Treatment
The 5. and last time of treatment(intervention of this study)
Number of Partcipants Who Experienced a Decrease in Symptoms With Their Late Sequela at 6 Month Follow-up
6 month after finishng the craniosacral treatment( intervention of this study)
Study Arms (1)
Cranoisacral Therapy Receivers
EXPERIMENTALThe participants will receive 50 minutes of treatment of craniosacral therapy once a week in 5 weeks. The treatment will follow the protocol "avenue of expression" end step 2c and 2c in "Ten step protocol". Instructions in home exercises is given. Before treatment the participants fill in the questionnaire "Xerostomia questionnaire after min 3 months" - a Danish standardized questionnaire of xerostomia used in hospitals. They will fill in this questionnaire again after ending their 5 treatment sessions, and again 6 months later as a follow up. They will also take notes in a diary of any side effects experienced during the treatment period. I will take their full medical history the first time we meet, I will take notes describing my treatment after every treatment session, including notes of the effects (positive and negative) that the participant has noticed.
Interventions
Manual treatment, 5 grams, on the airway system, the throat, the neck, the meninges, the cranial nerve sleeves, the visceral cranium, and the soft tissue in the mouth.
Exercises targeting upper posture and breathing exercises. The exercises is given when the therapist has reached some anatomical milestones in the treatment protocol. For example, an exercise with diaphragmatic breathing is given after manual treatment of diaphragma.
Eligibility Criteria
You may qualify if:
- Have finished radiation treatment and/or surgery for oro-pharyngeal head or necḱ cancer at least two years before enrolling the project
- They shall score at least 4 on an xerostomia numeric scale where 0 is no xerostomia.
You may not qualify if:
- Persons who by surgery have got both their submandibular saliva glands removed.
- Persons with known intercranial aneurism.
- Persons who have got a skull fracture during the last 6 months.
- Women who are trying to get pregnant.
- Persons who have sequela after a trauma on their neck that needed hospitalization.
- People with hernia on medulla oblongata.
- I will wait to treat people until after one month after they have received any dural puncture, or after 12 weeks of pregnancy.
- If I during my journal procedure of my participant finds any signs of active disease, I will send them to their doctor and do not start my treatment before the doctors approval.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cathrine Rahbeklead
- Danish Cancer Societycollaborator
- DLHM - Danish Society for Mouth and Throat Cancercollaborator
- Danish Network for Mouth and Throat Cancercollaborator
Study Sites (2)
Center for Kræft og Sundhed
Copenhagen, 2200, Denmark
- Rahbek kraniosakralterapi -FysioDanmark Skødstrup
Skødstrup, Århus, 8530, Denmark
Related Publications (4)
Hoxbroe Michaelsen S, Gronhoj C, Hoxbroe Michaelsen J, Friborg J, von Buchwald C. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients. Eur J Cancer. 2017 Jun;78:91-102. doi: 10.1016/j.ejca.2017.03.006. Epub 2017 Apr 18.
PMID: 28431302BACKGROUNDGronhoj C, Jensen DH, Vester-Glowinski P, Jensen SB, Bardow A, Oliveri RS, Fog LM, Specht L, Thomsen C, Darkner S, Jensen M, Muller V, Kiss K, Agander T, Andersen E, Fischer-Nielsen A, von Buchwald C. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):581-592. doi: 10.1016/j.ijrobp.2018.02.034. Epub 2018 Mar 6.
PMID: 29678523BACKGROUNDLauridsen MC, Torsleff KR, Husted H, Erichsen C. Physiotherapy treatment of late symptoms following surgical treatment of breast cancer. Breast. 2000 Feb;9(1):45-51. doi: 10.1054/brst.1999.0087.
PMID: 14731584BACKGROUNDDirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia. Support Care Cancer. 2007 Dec;15(12):1429-36. doi: 10.1007/s00520-006-0210-y. Epub 2007 Jan 18.
PMID: 17235501BACKGROUND
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
1 participant received intervention, but was excluded before analysis because it was discovered afterwards that this participant was never eligible for inclusion (because of low score (3) in the xerostomia vas-scale at baseline - inclusion criterium was \>= 4) While scoring the xerostomia questionnaire 6 answers have inconclusive scores (either two values, or no values at all). These cases were not included when calculating the mean.
Results Point of Contact
- Title
- Cathrine Rahbek
- Organization
- Rahbek FYS
Study Officials
- PRINCIPAL INVESTIGATOR
Cathrine T Rahbek, Cst t
Rahbek KST
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Masking Details
- The person who does the statistic analysis will not have participated in the treatments and will not have met the participants.
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Physio Therapist, Craniotherapist cst t
Study Record Dates
First Submitted
October 4, 2021
First Posted
May 31, 2023
Study Start
March 18, 2022
Primary Completion
January 20, 2023
Study Completion
November 27, 2023
Last Updated
May 14, 2025
Results First Posted
May 14, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- I will keep the data at my desktop for at least 10 years
- Access Criteria
- They will be in Danish and will not be on a website - i will translate them if you contact me on my mail address.
The plan is to get the results released as an research article in a peer reviewed journal. If possible, the results will be accessible for everyone who is interested. I will also share it in Danish networks for interdisciplinary colleagues, and with relevant patient associations